Completed
Nanotechnology holds promise for cancer screening, chemotherapy, cancer diagnosis, and the creation of combination products such as theranostics. Significant research funding is currently devoted to research in nanomedicine, providing opportunities for scientific advances and new products. Even so, there are substantial challenges to overcome in clinical research as well as translational science hurdles. The goal of the workshop was to describe nanomedicine and its potential risks and benefits, and well as to discuss the current state of standards and regulation for nanomedicine in oncology.
Featured publication
Workshop
ยท2011
One way scientists are working to overcome challenges in cancer treatment and improve cancer care is through nanotechnology. Nanotechnology, engineered materials that make use of the unique physical properties, presents a new array of medical prospects that will revolutionize cancer prevention, diag...
View details
Description
The National Cancer Policy Forum intends to sponsor a public workshop addressing issues related to two potential foci:
1) Implementation of a regulatory framework around nanomedicine: internationalization, harmonization, and safety, including topics such as
a. Government-led initiatives
b. International initiatives
c. Manufacturer intellectual property, competitiveness, and public safety concerns
d. Perspectives from other countries
2) Issues and implications for nanomedicine: translational science and clinical research, including topics such as
a. Government-led initiatives
b. Challenges of interdisciplinary collaboration
c. Need for clinical researcher, clinicians, and public understanding of risks and benefits of nanomedicine.
An ad hoc committee will plan and conduct the workshop, which may include presentations and discussion on: introduction to nanotechnology and nanomedicine, in addition to sessions relevant to the foci listed above. The workshop which is to be held at an open meeting of the Forum on July 12th and 13th, 2010, will feature invited presentations and discussion and will serve to inform the Forum. An individually-authored summary of the workshop will subsequently be prepared by a designated rapporteur.
Contributors
Sponsors
American Association for Cancer Research
American Cancer Society
American Society of Clinical Oncology
Association of American Cancer Institutes
C-Change
Centers for Disease Control and Prevention (CDC)
CEO Roundtable on Cancer
National Cancer Institute
Novartis Oncology
Oncology Nursing Society
Staff
Christine Micheel
Lead
Sharyl Nass
Lead
Erin Balogh
Lead
Patrick Burke
Major units and sub-units
Center for Health, People, and Places
Lead
Institute of Medicine
Lead
Board on Health Care Services
Lead
Health Care and Public Health Program Area
Lead